These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22284726)

  • 1. Value of CYP2C19 *2 and *17 genotyping in clinical practice. Promising but not ready yet.
    Bergmeijer TO; ten Berg JM
    Rev Esp Cardiol (Engl Ed); 2012 Mar; 65(3):205-7. PubMed ID: 22284726
    [No Abstract]   [Full Text] [Related]  

  • 2. Current status of clopidogrel pharmacogenomics.
    Giusti B; Gori AM; Marcucci R; Abbate R
    Pharmacogenomics; 2012 Nov; 13(15):1671-4. PubMed ID: 23171330
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis.
    Liu YP; Hao PP; Zhang MX; Zhang C; Gao F; Zhang Y; Chen YG
    Thromb Res; 2011 Dec; 128(6):593-4. PubMed ID: 21794898
    [No Abstract]   [Full Text] [Related]  

  • 4. CYP2C19 genotype and outcomes of clopidogrel treatment.
    Siasos G; Tousoulis D; Stefanadis C
    N Engl J Med; 2011 Feb; 364(5):481-2. PubMed ID: 21288101
    [No Abstract]   [Full Text] [Related]  

  • 5. CYP2C19 genotype and outcomes of clopidogrel treatment.
    Geisler T; Bigalke B; Schwab M
    N Engl J Med; 2011 Feb; 364(5):481; author reply 482. PubMed ID: 21288102
    [No Abstract]   [Full Text] [Related]  

  • 6. Personalised antiplatelet therapy: are we ready for prime time? Data from China.
    Li J; Huo Y
    EuroIntervention; 2013 Jul; 9(3):296-8. PubMed ID: 23872644
    [No Abstract]   [Full Text] [Related]  

  • 7. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.
    Peters BJ; Harmsze AM; ten Berg JM; Maitland-van der Zee AH; Tjoeng MM; de Boer A; Deneer VH
    Pharmacogenomics; 2011 Feb; 12(2):141-4. PubMed ID: 21332306
    [No Abstract]   [Full Text] [Related]  

  • 8. Clopidogrel in acute coronary syndrome: to genotype or not?
    Storey RF
    Lancet; 2009 Jan; 373(9660):276-8. PubMed ID: 19108882
    [No Abstract]   [Full Text] [Related]  

  • 9. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome.
    Tello-Montoliu A; Jover E; Marín F; Bernal A; Lozano ML; Sánchez-Vega B; Pastor FJ; Hurtado JA; Valdés M; Vicente V; Rivera J
    Rev Esp Cardiol (Engl Ed); 2012 Mar; 65(3):219-26. PubMed ID: 22116003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical assessment, platelet reactivity measurement or genetic testing after acute coronary syndrome? What benefits the patient?
    Keßler M; Rottbauer W; Koenig W
    EuroIntervention; 2013 Jul; 9(3):299-301. PubMed ID: 23872645
    [No Abstract]   [Full Text] [Related]  

  • 12. Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.
    Fuster V; Sweeny JM
    JAMA; 2010 Oct; 304(16):1839-40. PubMed ID: 20978263
    [No Abstract]   [Full Text] [Related]  

  • 13. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.
    Frére C; Cuisset T; Gaborit B; Alessi MC; Hulot JS
    J Thromb Haemost; 2009 Aug; 7(8):1409-11. PubMed ID: 19496924
    [No Abstract]   [Full Text] [Related]  

  • 14. Establishment of a CYP2C19 genotyping assay for clinical use.
    Cervinski MA; Schwab MC; Lefferts JA; Lewis LD; Lebel KA; Tyropolis AM; Pflueger SM; Tsongalis GJ
    Am J Clin Pathol; 2013 Feb; 139(2):202-7. PubMed ID: 23355205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines.
    Steinhubl SR
    Circulation; 2010 Feb; 121(4):481-3. PubMed ID: 20083686
    [No Abstract]   [Full Text] [Related]  

  • 18. Clopidogrel and CYP2C19 testing: ready for clinical prime time?
    Hulot JS; Hajjar R; Montalescot G
    Clin Chem; 2012 Jan; 58(1):154-7. PubMed ID: 21940658
    [No Abstract]   [Full Text] [Related]  

  • 19. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?
    Bhatt DL
    JAMA; 2009 Aug; 302(8):896-7. PubMed ID: 19706866
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Taubert D; Bouman HJ; van Werkum JW
    N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.